IMPACT Cell and Gene Therapy Meeting
MARCH 21 – 22, 2024
Joint Session ISCT
Universidad de los Andes – Santiago de Chile
Aula Magna Edificio Biblioteca, Monseñor Álvaro del Portillo N°12.455, Las Condes.
Meeting topics: cell therapy, cell therapy manufacturing and cell based imunotherapies, T cell based therapies, vaccine development for cancer immunotherapy, immunoregulatory therapies for autoimmune diseases.
DESCRIPTION OF THE MEETING
The meeting aims to share the most exciting advances in cell therapy manufacturing and immunotherapy, with a special focus on the development of CAR T cells and cellular immunotherapies.
This meeting is organized by the IMPACT Center of Excellence in collaboration with the Central and South American Regional Executive Committee of the International Society for Cell and Gene Therapy (ISCT) and Clinica Universidad de los Andes.
This event offers a unique combination of networking opportunities for scientists, clinicians, academics, government and industry.
For this, we will have the participation of experts in the field.
CRISTINA PUIG-SAUS (EE.UU.)
Assistant Adjunct Professor at the University of California, Los Angeles (UCLA). Dr. Puig-Saus is also a Senior Fellow with the Parker Institute for Cancer Immunotherapy (PICI) and a member of the Jonsson Comprehensive Cancer Center (JCCC) and the Broad Stem Cell Research Center (BSRCR). Dr. Puig-Saus now leads her laboratory at UCLA, focused on the design and clinical translation of novel TCR and CAR-engineered T-cell therapies for cancer treatment.
BRUCE LEVINE (EE.UU. – Hybrid)
Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. Dr. Levine is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, and he is co-inventor on 31 issued US patents.
JONAS PALUDO (EE.UU. – Hybrid)
Hematologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. He received his medical degree from Health Sciences Federal University of Porto Alegre and has been in practice between 11-20 years. Dr. Jonas Paludo has expertise in treating chronic leukemia, lymphoma, among other conditions.
JULIAN MOLINA (EE.UU.)
Oncologist in Rochester, Minnesota and is affiliated with Mayo Clinic-Rochester. He received his medical degree from Pontifical Bolivarian University and has been in practice for more than 20 years. Dr. Julian R. Molina has expertise in treating lung cancer, lymphoma, small intestine/colorectal cancer, among other conditions.
ARKADIUSZ Z. DUDEK (EE.UU. – Hybrid)
Oncologist in Rochester, Minnesota and is affiliated with multiple hospitals in the area, including Mayo Clinic-Rochester and Regions Hospital. Dr. Arkadiusz Z. Dudek has expertise in treating lung cancer, prostate cancer, small intestine/colorectal cancer, among other conditions.
MARTIN BONAMINO (Brazil)
Ph.D. in Biological Chemistry and researcher at the National Cancer Institute and Specialist at the Oswaldo Cruz Institute Foundation, where he participates in the coordination of the FioCâncer Network. He is Researcher at Instituto Nacional de Cancer (INCA), and member of the Global Outreach Committee of the American Society of Cell and Gene Therapy (ASGCT), of the South and Central America Legal and Regulatory Affairs Committee of the International Society for Cell and Gene Therapy (ISCGT) and of the National Network of Specialists in Advanced Therapies (RENETA).
PATRICK HANLEY (EE.UU.)
Chief and director of the Cellular Therapy Program. He is also an associate professor of pediatrics in the Center for Cancer and Immunology research at the Children’s National Research Institute and member of the Center for Cancer and Blood Disorders and the Division of Blood and Marrow Transplantation. As Chief and Director of the Cellular Therapy Program, Dr. Hanley works with investigators in an iterative manner to discover, optimize, and manufacture novel cell and gene therapies.
VIRGINIA PICANCO (Brazil)
PhD in Biomedical Research from the Medical University of Sao Paulo (Brazil). She is currently a researcher and Associate Professor at the Blood Center of Ribeirão and the Center for Cellular Therapies (CTC) of the University of Sao Paulo. She has experience in molecular biology, cell culture, recombinant proteins and gene expression analysis.
ALVARO LLADSER (Chile)
PhD in Biomedical Sciences from Universidad de Chile, and did his postdoctoral training at the Cancer Center of the Karolinska Institute, Sweden. Dr. Lladser directs the Laboratory of Immunoncology at the Fundacion Ciencia & Vida and since 2019 he is Associate Professor at the Faculty of Medicine and Science of Universidad San Sebastián. His research focuses on unraveling the complex molecular and cellular networks that underlie effective T cell-mediated antitumor immunity by analyzing human samples using high-dimensional transcriptomics and phenotypic analyses, as well as ex vivo functional assays and in vivo tumor models.
FERNANDO EZQUER (Chile)
PhD in Sciences, mention in Cellular, Molecular Biology and Neurosciences from the University of Chile. He is currently Deputy Director of the Center for Regenerative Medicine of the Faculty of Medicine, Clínica Alemana Universidad del Desarrollo.
PATRICIA LUZ-CRAWFORD (Chile)
PhD in Biotechnology from the Universidad de Santiago de Chile and professor at the Universidad de los Andes. She has worked on the role of mitochondria and mitochondrial transfer derived from mesenchymal stem cells as potential therapeutic agents in inflammatory and degenerative diseases.
SOLEDAD MC-KEON (Chile)
Postdoctoral researcher at the CAR-T laboratory of the IMPACT Center, in charge of the CAR-T GMP manufacturing process. Biologist with expertise in vaccines and immunotherapies. During her PhD she specialized in the development of dendritic cell-based vaccines for melanoma, being part of the clinical trial of the Vaccimel vaccine for cutaneous melanoma.
CHARLOTTE HILL-MACHADO (Chile)
Dr. Hill received her PhD in Biological Sciences from the Pontificia Universidad Católica de Chile where she specialized in cancer immunotherapy and then joined the Immunology division of the Boston Childrens Hospital and the Pediatrics department of Harvard Medical School during her postdoctoral training to research Treg destabilization. Dr. Hill has recently joined the IMPACT center as the leading researcher of CAR T cell R&D, where she is implementing the CAR-T cell technology. She has also joined the ISCT and incorporated to the Immuno-Gene Therapy Committee as an ESP Leadership Development Program Member.
- Thursday, March 21st 08:30 – 18:00 hrs.
Day 1: “Cancer Immunotherapy Symposium”.
- Friday, March 22 09:00 – 18:00 hrs.
Day 2: “Immunotherapy Horizons: Pioneering Therapies from Concept to Clinic”.
Please complete the following registration FORM. We will send you the payment link via email:
- General Ticket USD120*
- Fellow/Postdoc Ticket USD 100
- Technologist Ticket USD 80
- Students Ticket USD 25**
*15% discount for ISCT members
**Important note for students: Please be prepared to provide a regular student certificate by 2024.
Special ISCT Membership Rates
We’re delighted to partner with the International Society for Cell & Gene Therapy (ISCT) to bring an exceptional offer exclusively to attendees of the CGT Meeting 2024. Join a vibrant global community dedicated to advancing cell and gene therapy. Enjoy a wealth of resources, networking opportunities, and the latest industry insights at half the regular membership cost.
For CGT Meeting 2024 Registered Attendees Only:
- Regular E-Membership: Just USD 87.50 (Regularly USD 175)
- Fellow/Resident/Postdoc E-Membership: Only USD 32.50 (Regularly USD 65)
- Student E-Membership: A great value at USD 25.00
- Technologist E-Membership: Reduced to USD 62.50 (Regularly USD 125)
How to Avail of This Offer:
Receive Your Payment Link: After registration, we’ll send you an email with a unique link to complete your discounted ISCT membership subscription.
- Setting the standards in Cell and Gene Therapy
- Publish with Impact
- Exclusive member discounts
- Building Tomorrow’s Cell & Gene Therapy Leaders
- Celebrating achievements
- A truly global network
- Building sector-wide consensus by spearheading collaborations
More information: https://www.isctglobal.org/join
REGISTRATION AND ABSTRACT SUBMISSION:
* Deadline for abstract submission: 15 March 2024.
For abstract submissions please visit this LINK which hosts the abstract submission form.
For abstract submissions please consider the following information:
- The abstract must be written in English, Times New Roman, 12 point font.
- The abstract should be self-contained and written for a general scientific audience.
- The abstract should be no more than 300 words in length, including all sections requested below: HEADER includes: title (maximum 250 characters), authors (First Name Last Name; separated by comma. Each author must be followed by a number corresponding to the institution), institution(s) (maximum 400 characters) where the submitted work was developed and e-mail address. Body of the abstract, including (Maximum 2000 characters): Introduction, Material and Methods, Results, Discussion and Acknowledgements.
- Deadline for abstract submission: 15 March 2024.
- Abstracts will be selected for short oral presentations of 15 minutes.
These travel awards are intended to provide opportunities for graduate students, postdoctoral fellows, and young investigators to participate in the Impact Cell and Gene Therapy Meeting.
While it is not necessary to submit an abstract to receive a Travel Award, it is strongly encouraged.
There will be 2 Travel Awards for national applicants in the amount of US$200 each, and 1 Travel Award within Latin America in the amount of US$500.
More information: IMPACT-CGT Travel Awards
Scientific Organizing Committee (SOC):
- Charlotte Hill-Machado, Center IMPACT – Universidad de los Andes.
- Maroun Khoury, Director Center IMPACT – Universidad de los Andes.
- Francisca Alcayaga, Center IMPACT – Universidad de los Andes.
Meeting Organising Committee (Staff):
- Miguel Rebolledo, CEO Center IMPACT.
- Natalie Huerta, Communications Manager Center IMPACT.
- Viviana Berríos, Executive Assistant Center IMPACT.
For inquiries or more information write to: [email protected]